This open access book provides a concise overview of a range of aspects related to urinary stents. Sections within the work cover clinical and recent technological advancements in the field. Chapters feature detailed coverage of the different surgical, pharmacological and palliative treatments currently available. Insight is also given on current limitations of urinary stents and how these can be overcome by utilizing anti-biofilm coatings; new biomaterials, drug-eluting stents, and biodegradable stents. Therefore, enabling the reader to systematically gain a detailed understanding of the subject.
Urinary Stents is a practical, multi-disciplinary focused resource on the complications and applications of ureteral, urethral and prostatic stents in day-to-day clinical practice. A vital read for all medical professionals and researchers who work in this area.
Dr Federico Soria. Endourology Research Coordinator in Jesus Usón Minimally Invasive Surgery Centre Foundation, Cáceres, Spain. Principal Inventor in 3 patents about Ureteral stents. Involvement in more than 20 research projects in urinary stents innovation as main proponent and Principal researcher, competitive funds (1999-2020). Chairman (2017-2021) Cost Action (CA16217). European network of multidisciplinary research to improve the urinary stents (European Cooperation in Science and Technology. Brussels-Belgium).
Dr Duje Rako, MD, FEBU is consultant urological surgeon working in private practice at present with previous posts in University Hospital Dubrava, Zagreb, Croatia and Countess of Chester NHS Foundation Trust, Manchester, UK. He hreceived his MD title from Zagreb university School of Medicine in 2006, passed urology qualification in 2013 and FEBU exam in 2015. He has considerable experience in open cancersurgery and all endoscopic procedures for stones and urogenital tumors with special interest in stone disease and endoscopy.
Prof. Dr. Petra deGraaf is an Assistant Professor at the Urology department in the University Medical Center at Utrecht, The Netherlands. Her current research goal is to generate a tissue engineered (TE) source of urethra tissue for use in urethral reconstruction. Ideally, a TE urethra mimics the native urethra, consists of multiple cell layers of different origin, protects the underlying tissue as an efficient barrier from urine, is vascularized and resistant to mechanical forces during surgery. As in many patients undergoing urethral reconstruction surgery, the surrounding corpus spongiosum is either absent (in hypospadias patients) or affected by fibrosis. By aiming to integrate the corpus spongiosum in the TE graft, a natural vascular environment is provided. Dr deGraaf's molecular background helps to bring the science to life: experience and knowledge acquired through the years will lead to solutions for health and disease.
